Analyst initiates a bullish perspective on Dynavax, ascribing a probability of 95% approval for its lead asset.
Analyst sees higher ad revenue per daily active user growth ahead for Snap and attractive valuation.
Analyst says share weakness does not stem from encouraging news, but points to other underlying concerns.
Supernus investors are running for the hills, but analyst sees elimination of 18 mg dose as a good move.
Though Teva shares took a hit upon the news, the analyst sees an upside to expectations in the distance.
Analyst believes impressive Phase 3 data read-out bolsters expectations for lefamulin’s peak sales potential.
Analyst expected NDA acceptance- but believes the FDA news importantly lowers regulatory risk for ARRY.
Analyst dismisses negative publicity haunting HIIQ as unjustified extrapolation from past settlements.
Forecasting a potential $500 million yearly sales opportunity ahead, the analyst lifts price target on Array.
Analyst Louise Chen cheers that new Danish CEO means “good news” for Tesla investors.